Roblon A/S (CPSE:RBLN B) agreed to acquire VAMAFIL, spol. s r.o. for €8 million on November 9, 2021. Roblon has secured €10.85962 in long-term credit facilities to support the acquisition of Vamafil and the Group's growth strategy in general.

The company has annual revenue of between €4.5m and €5m. The completion of the transaction is subject to confirmatory due diligence on a couple of matters, retention of management and other customary closing conditions. The acquisition date is 3 January 2022.